

# Grŵp Strategaeth Meddyginiaethau Cymru Gyfan All Wales Medicines Strategy Group



## Final Appraisal Recommendation Advice No: 1022 – April 2022

### Teriflunomide (AUBAGIO®) 7mg and 14 mg film-coated tablets

#### Submission by Aventis Pharma Ltd

#### Recommendation of AWMSG

**Teriflunomide (AUBAGIO®) is recommended as an option for restricted use within NHS Wales.**

**Teriflunomide (AUBAGIO®) is licensed for the treatment of paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis.**

**Teriflunomide (AUBAGIO®) is restricted for use for the treatment of active relapsing–remitting multiple sclerosis (normally defined as 2 clinically significant relapses in the previous 2 years) in paediatric patients aged 10 years and older, who do not have highly active or rapidly evolving severe relapsing–remitting multiple sclerosis.**

**This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent or lower than the PAS price.**

#### Additional note(s):

- See NICE guidance for teriflunomide for the treatment of adults with active relapsing–remitting multiple sclerosis (TA303, originally published January 2014).

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 4033), which includes the All Wales Therapeutics and Toxicology Centre (AWTTC) assessment, AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:  
All Wales Medicines Strategy Group Final Appraisal Recommendation – 1022:  
Teriflunomide (AUBAGIO®) 7mg and 14 mg film-coated tablets, April 2022.